Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3

Rhinology

Volumn 44, Issue 2, 2006, Pages 145-150

  Olze, Heidi ^a,b   Forster U ^a   Zuberbier, T ^a   Morawietz, L ^a   Luger, E O ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Global Allergy and Asthma European Network (GA2LEN)   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

Eosinophils; Eotaxin; Eotaxin 2; Eotaxin 3; Polyposis nasi

Indexed keywords

ACETYLSALICYLIC ACID; EOTAXIN; EOTAXIN 2; EOTAXIN 3; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MALE; NOSE ALLERGY; NOSE POLYP; PATHOGENESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FAMILY; SAMPLE; TISSUE HOMOGENATE; TURBINATE;

ADULT; CHEMOKINE CCL11; CHEMOKINE CCL24; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; MALE; NASAL POLYPS;

EID: 33744972881     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Allen JS, Eisma R, La Freniere D. Characterization of the eosinophil chemokine RANTES in nasal polyps. Ann Otol Rhinol Laryngol 1998; 107(5): 416-420.
2. Bachert C, Hauser U, Prem B, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997; 99: 837-842.
3. Bachert C, Wagenmann M, Rudack C, van Cauwenberge P. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53: 2-13.
4. Caversaccio M, Hartnell A, Calnan D et al. The role of chemokines in nasal polyps. Schweiz Med Wochenschr 2000; Suppl. 125: 92-95.
5. Caversaccio M, Uguccioni M, Hartnell A, Conroy D. Chronic immunological rhinosinusitis: general aspects, cytokines, chemokines and possibile therapeutic consequences. Otorhinolaryngol Nova 2003; 12(2): 52-62.
6. Hamilos DL, Leung DY, Wood R et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92: 39-48.
7. Hamaguchi Y, Suzumura H, Arima S, Sakakura Y. Quantitation and immunocytological identification of interleukin-1 in nasal polyps from patients with chronic sinusitis. Int Arch Allergy Immunol 1994; 104 (2): 155-159.
8. Hamilos DL, Leung DY, Wood R et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995; 96: 537-544.
9. Hamilos DL, Leung DY, Wood R,et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis is associated with endothelial VCAM-1 upregulation and expression of TNF-alpha. Amer J Respir Cell Mol Biol 1996; 15: 443-450.
10. Hamilos DL, Leung DY, Huston DP et al. GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998; 28(9): 1145-1152.
11. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999; 163(3): 1545-1551.
12. Lee CH, Rhee CS, Min YG. Cytokine gene expression in nasal polyps. Ann Otol Rhinol Laryngol 1998; 107(8): 665-670.
13. Maune S; Meyer JE. The role of CC chemokines in chronic sinusitis. Otorhinolaryngol Nova 2003;12(2): 63-70.
14. Min YG, Lee CH, Rhee CS. Inflammatory cytokine expression on nasal polyps developed in allergic and infectious rhinitis. Acta Otolaryngol 1997; 117(2): 302-306.
15. Minshall EM, Cameron L, Lavigne F et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997; 17(6): 683-690.
16. Nonaka M, Pawankar R, Saji F, Yagi T. Eotaxin synthesis by nasal polyp fibroblasts. Acta Otolaryngol 1999; 119(7): 816-820.
17. Rudack C, Stoll W, Bachert C. Cytokines in nasal polyposis, acute and chronic sinusitis. Amer J Rhinol 1998; 12 (6): 383-388.
18. Rudack C, Vagenmann M, Hauser U, Ganzer U. Zytokinmuster bei verschiedenen Formen der Sinusitis. Laryngo-Rhino-Otol 1998; 77(1): 34-37.
19. Rudack C, Bachert C. Zytokine and Chemokine bei Nasennebenhöhlenerkrankungen. Laryngo-Rhino-Otol 1999; 78: 481-490.
20. Ebisawa M, Bochner BS, Georas SN, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol 1992; 149 (12): 4021-4028.
21. Ebisawa M, Liu MC, Yamada T et al. Eosinophil transendothelial migration induced by cytokines. II. Potentiation of eosinophil trans endothelial migration by eosinophil-active cytokines. J Immunol 1994; 152 (9): 4590-4596.
22. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol 1994; 153 (5): 2153-2160.
23. Jose PJ, Griffits-Johnson DA, Collins PD et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1993; 179: 881-887.
24. Kapp A, Zeck-Kapp G, Czech W, Schöpf E. The chemokine RANTES is more than a chemoattractant: characterization of it's effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J Invest Dermatol 1994; 102: 906-914.
25. Ponath PD, Qin S, Ringler DJ et al. Cloning of the human eosinophil chemoattractant eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97: 604-612.
26. Schleimer RP, Sterbinsky SA, Kaiser J et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1J Immunol 1992; 148 (4): 1086-1092.
27. Sehmi R, Cromwell O, Wardlaw J, Moqbel R, Kay B. Interleukin-8 is a chemoattractant for eosinophils purified from subjects with a blood eosinophilia but not from healthy subjects. Clin Exp Allergy 1994; 23: 1027-1031.
28. van Damme J. Interleukin-8 and related molecules. In: Thompson AW, ed. The cytokine handbook. London: Academic Press, 1991; 201-214.
29. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 149: 452-459.
30. Forssmann U, Uguccioni P, Loetscher CA, Dahinden H, Baggiolini M. Eotaxin-2, a novel CC- chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997; 185: 2171-2176.
31. Kitaura M, Nakajama T, Imai T et al. Molecular cloning of human eotaxin, an eosinophil-specific CC chemokine, and identification of a specific receptor, CC chemokine receptor 3. J Biol Chem 1996; 271: 7725-7730.
32. Kitaura M, Suzuki N, Imai T, et al. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999; 274(39): 27975-27980.
33. Dulkys Y, Schramm G, Kimmig D et al. Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils. J Invest Dermatol 2001; 116(4): 498-505.
34. Ying S, Meng Q, Zeibecoglou K et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999; 163(11): 6321-6329.
35. Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Nishi T. A novel human CC-chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999; 163: 1602-1610.
36. Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol 1995; 167(Suppl.): 17-21.
37. Kaplan AP. Chemokines, chemokine receptors and allergy. Int Arch Allergy Immunol 2001; 124(4): 423-431.
38. Bartels J, Schluter C, Richter E, Christophers E, Schröder JM. Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem Biophys Res Commun 1996; 225(3): 1045-1051.
39. Ying S, Robinson DS, Meng Q, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163(7): 3976-3984.
40. Pods R, Ross D, van Hulst S et al. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58(11): 1165-1170.
41. Nakajima T, Yamada H, Likura M et al. Intracellular localization and release of eotaxin from normal eosinophils. FEBS Lett 1998; 434(3): 226-30.
42. Ying S, Meng Q, Taborda-Barata L et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 1996; 26(1): 70-76.